Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)

• Published in: Clinical endocrinology (Oxford) 2009-06, Vol.70 (6), p.838-846
• Main Authors: Chapman, Ian, Greville, Hugh, Ebeling, Peter R., King, Susannah J., Kotsimbos, Tom, Nugent, Patricia, Player, Rosie, Topliss, Duncan J., Warner, Janet, Wilson, John W.
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; Cystic Fibrosis - complications; Cystic Fibrosis - drug therapy; Diphosphonates - therapeutic use; Double-Blind Method; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; Humans; Imidazoles - therapeutic use; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Osteoarticular system. Muscles; Osteoporosis - drug therapy; Osteoporosis - etiology; Placebos; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Vertebrates: endocrinology
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/j.1365-2265.2008.03434.x

Summary Objective  Reduced bone mineral density (BMD) and increased rates of atraumatic fracture are observed in cystic fibrosis (CF) patients, causing increasing morbidity as this population ages. The study aimed to assess the safety, tolerability and effect on BMD of intravenous zoledronate in adults with CF and osteopaenia. Design  Randomized, double‐blind, placebo‐controlled clinical trial. Setting  Adult CF outpatient clinics at two hospitals. Patients  Twenty‐two non‐transplanted CF patients aged ≥ 18 years with a bone densitometry T‐score of